Literature DB >> 33813277

GRSF1 promotes tumorigenesis and EMT-mediated metastasis through PI3K/AKT pathway in gastric cancer.

Baohua Wang1, Lili Wang2, Yixun Lu1, Wenquan Liang2, Yunhe Gao2, Hongqing Xi2, Lin Chen3.   

Abstract

It is vital to identify effective therapeutic targets and explore the underlying mechanisms to curb the progression of Gastric cancer (GC) and improve the prognosis of GC patients. Guanine-rich RNA sequence binding factor 1 (GRSF1) is a member of the RNA-binding protein family. The present study showed that GRSF1 knockdown suppressed GC cells proliferation, migration and invasion in vitro, while GRSF1 overexpression enhanced the proliferation, migration and invasion of GC cells. Meanwhile, knockdown of GRSF1 inhibited tumor growth and tumor metastasis in vivo. Furthermore, we demonstrated that GRSF1 induced epithelial-mesenchymal transition (EMT) and activated PI3K/AKT pathway in vitro and in vivo through gain and loss of function. In conclusion, we demonstrated that GRSF1 promotes tumorigenesis and EMT-mediated metastasis through PI3K/AKT pathway in GC. Our study for the first time identified the functions of GRSF1 serving as an oncogene in GC, which may be a potential effective therapeutic target and malignant indicator in GC.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  EMT; Gastric cancer; Guanine-rich RNA sequence binding factor 1 (GRSF1); PI3K/AKT

Year:  2021        PMID: 33813277     DOI: 10.1016/j.bbrc.2021.03.121

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Network-based approach to identify prognosis-related genes in tamoxifen-treated patients with estrogen receptor-positive breast cancer.

Authors:  Yanyan Wang; Xiaonan Gong; Yujie Zhang
Journal:  Biosci Rep       Date:  2021-09-30       Impact factor: 3.840

2.  GRSF1 predicts an unfavorable prognosis and promotes tumorigenesis in lung adenocarcinoma based on bioinformatics analysis and in vitro validation.

Authors:  Rong Huang; Lin Xu; Qichen Chen; Amannisa Tuersuntuoheti; Luying Su; Fu Xu; Yanqing Bi; Yiqiao Deng; Wei Song; Hong Zhao; Xu Che
Journal:  Ann Transl Med       Date:  2022-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.